Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$404.42 USD

404.42
197,494

-2.82 (-0.69%)

Updated Jul 2, 2024 04:00 PM ET

After-Market: $404.35 -0.07 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 249)

Industry: Medical Services

Better trading starts here.

Zacks News

Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch

Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.

Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?

Labcorp's (LH) concentrated development in high-growth areas and strategic partnerships appear encouraging.

National Vision (EYE) Gains Market Share Despite Macro Woes

National Vision (EYE) continues to execute core growth initiatives and further invest in strengthening competitive advantages.

Thermo Fisher (TMO) Expands Central Lab Footprint in Kentucky

Thermo Fisher (TMO) announces expansion of its central laboratory operations in Kentucky. The new space in Covington will be in addition to its existing central lab in Highland Heights.

Community Health (CYH) & Cost Plus Drugs Expand Collaboration

Community Health (CYH) is now set to source drugs from the Cost Plus Drugs Marketplace under the new expanded partnership.

Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is it Wise to Hold Teleflex (TFX) Stock in Your Portfolio Now?

Teleflex (TFX) holds strong momentum in the Interventional arm and a favorable solvency. Yet, macroeconomic impacts and competitive environment trigger concerns.

QIAGEN (QGEN) Backs New AAP Guidelines Supporting QFT-Plus Test

QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages.

Neogen (NEOG) Expands in Food Safety With Petrifilm Feeder Launch

Neogen (NEOG) launches Petrifilm Automated Feeder, which allows automatic feeding and enumeration of up to 300 petrifilm plates in 33 minutes. The system improves the efficiency of food safety testing labs.

Thermo Fisher's (TMO) New Launch Speeds Up pDNA Purification

Thermo Fisher (TMO) introduces the Thermo Scientific KingFisher PlasmidPro, the fully automated maxi-scale pDNA purification system.

Charles River's (CRL) RMS Growth Aids Amid FX Headwind

Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.

Quest Diagnostics (DGX) Inks Deal to Acquire Allina Health

Quest Diagnostics (DGX) signs an agreement to acquire Allina Health's select laboratory assets. The deal is aimed at expanding Quest Diagnostics' laboratory services across Minnesota and western Wisconsin.

Medpace (MEDP) Stock Sinks As Market Gains: Here's Why

In the latest trading session, Medpace (MEDP) closed at $405.33, marking a -0.53% move from the previous day.

Bruker's (BRKR) Strategic Buyouts Aid Amid Macroeconomic Woes

Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand, further bolstered by the addition of Inscopix's neuroscience research tools.

Boston Scientific (BSX) DBS Programming Software Gets CE Mark

Boston Scientific (BSX) secures CE Mark for the DBS image-guided programming software, Vercise Neural Navigator 5.

Is It Apt to Hold Quest Diagnostics (DGX) Stock for Now?

Strength in the core business bodes well for Quest Diagnostics (DGX). However, mounting debt levels and reduced COVID-19 testing revenues pose concerns.

Charles River (CRL) Inks CDMO Deal With Gates Institutes

Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.

Asensus Surgical (ASXC) Announces New Hospital Tie-Up on Senhance

Asensus Surgical (ASXC) announces an agreement with St. Marianna University School of Medicine Yokohama City Seibu Hospital to lease its Senhance Surgical System.

Illumina (ILMN) Rises on Conclusion of GRAIL Divestment

With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.

Medtronic (MDT) Shares Positive Data for MiniMed 780G System

Medtronic (MDT) presents more compelling data showcasing the benefits of the MiniMed 780G system.

Abbott's (ABT) EPD Expansion Continues Despite FX Headwind

Banking on the successful execution of its Branded Generic operating model, Abbott's (ABT) EPD is well-positioned for sustained growth in many of the growing pharmaceutical markets.

Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval

Valneva's (VALN) IXCHIQ, the world's only licensed chikungunya vaccine, is a critical tool in combating this public health threat.

Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes

Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.

IDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds

IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.

Quest Diagnostics (DGX) Gains From New M&As Amid Competition

In Physician Lab Services, Quest Diagnostics (DGX) is benefiting from the broad-based return to care, overall market growth and share gains driven by the competitive strength of its scale and innovative offerings.